Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

A proof of concept for structure-based vaccine design targeting RSV in humans

(2019) Michelle C. Crank et al.   SCIENCE

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

(2018) Dan H Barouch et al.   LANCET

Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

(2018) Joseph B. Domachowske et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study

(2018) Jacqueline U. McDonald et al.   VACCINE

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

(2017) Judith Falloon et al.   JOURNAL OF INFECTIOUS DISEASES

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age

(2017) Allison August et al.   VACCINE

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

(2017) Louis Fries et al.   Immunity & Ageing

Hospitalizations for respiratory syncytial virus (RSV) among adults in the United States, 1997 - 2012

(2017) Susan T. Pastula et al.   Open Forum Infectious Diseases

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention

(2016) Lindsey R. Baden et al.   ANNALS OF INTERNAL MEDICINE

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

(2016) Iain D. Milligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

(2016) Judith Falloon et al.   VACCINE

Novel antigens for RSV vaccines

(2015) Barney S Graham et al.   CURRENT OPINION IN IMMUNOLOGY

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

(2015) Gregory M. Glenn et al.   JOURNAL OF INFECTIOUS DISEASES

Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

(2015) Joan O. Ngwuta et al.   Science Translational Medicine

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

(2015) Anders Krarup et al.   Nature Communications

Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy

(2014) William Wold et al.   CURRENT GENE THERAPY

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

(2013) J. S. McLellan et al.   SCIENCE

Strategic priorities for respiratory syncytial virus (RSV) vaccine development

(2013) L.J. Anderson et al.   VACCINE

Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein

(2012) Anu Cherukuri et al.   Clinical and Vaccine Immunology

Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach

(2012) Nathaniel D Lambert et al.   Expert Review of Vaccines

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

(2012) Lindsey R. Baden et al.   JOURNAL OF INFECTIOUS DISEASES

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

(2012) M. Magro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

(2011) Peter L. Collins et al.   VIRUS RESEARCH

Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to High‐Risk Elderly Individuals

(2008) Ann R. Falsey et al.   JOURNAL OF INFECTIOUS DISEASES